Stock Comparison

PFE vs UTHR

Pfizer Inc vs United Therapeutics Corp

Who's the better investment? Let's break it down.

The Verdict

UTHR takes this one.

This one's close — only 1.0 points separating them. UTHR wins by a hair, but both deserve a closer look.

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Winner

UTHR

United Therapeutics Corp

5.0

out of 10

Proceed with Caution

Want to compare any two stocks?

Valuation

PFE

Metric

UTHR

$146.4B

Market Cap

$23.6B

19.5

P/E Ratio

Lower may indicate better value

18.4

8.1

Forward P/E

17.2

1.5

Price/Book

N/A

7.1

EV/EBITDA

N/A

Profitability & Growth

PFE

Metric

UTHR

11.8%

Profit Margin

40.6%

74.8%

Gross Margin

86.6%

15.4%

Operating Margin

45.3%

8.4%

Return on Equity

19.2%

3.6%

Return on Assets

17.3%

1.4%

Revenue Growth

5.9%

$1.31

EPS

$27.09

Financial Health

PFE

Metric

UTHR

0.7

Debt-to-Equity

Lower = less leverage

N/A

1.2

Current Ratio

Above 1.0 is healthy

6.6

0.3

Beta

Lower = less volatile

0.6

6.8%

Dividend Yield

None

Risk Comparison

PFE

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Low

Regulatory

Medium

What Could Go Wrong

The biggest risk for Pfizer is the ongoing and accelerated erosion of revenue from key patent expirations and declining COVID-related product sales (Paxlovid/Comirnaty). If the pipeline of new product...

Red Flags

🚩Adjusted EPS declined -18% YoY in Q1 2026 despite revenue beat, indicating continued margin pressure...
🚩High reliance on successful pipeline execution to offset significant revenue declines from mature pr...
🚩Market Cap ($146.42B) requires an unrealistic 10x growth to over $1.4 trillion in 3-5 years, a scale...

UTHR

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Medium

Regulatory

Medium

What Could Go Wrong

The biggest risk is the continued commercial underperformance of key therapies, as evidenced by the Q1 2026 revenue miss of $15.9 million against estimates, potentially indicating weaker-than-expected...

Red Flags

🚩Q1 2026 revenue and EPS miss ($781.5M revenue vs $797.4M est.; $5.82 EPS vs $7.00 est.) indicating c...
🚩HC Wainwright cut Q2 2026 EPS estimate to $6.07 from $6.76 on May 18, 2026, signaling a more cautiou...
🚩Insider selling by CFO James Edgemond ($5.73M on May 26, 2026) and General Counsel Paul A. Mahon (mi...

Competitive Moat

PFE

Rating

🛡️ Wide

Trend

➡️ Stable

Intangible Assets/IP (Patents, regulatory approvals, proprietary compounds)Brand Power (Trust, reputation in healthcare)Cost Advantages (Scale in manufacturing and R&D)Switching Costs (Physician familiarity, established treatment protocols)

UTHR

Rating

🛡️ Narrow

Trend

📈 Expanding

Intangible Assets/IP (patents, regulatory approvals, clinical data for rare disease indications)Switching Costs (patients on chronic therapies, physician familiarity with complex treatments)Regulatory Expertise (navigating FDA approvals for rare diseases)

Investment Thesis

PFE4.0/10

If Pfizer's non-COVID product portfolio (e.g., Vyndaqel, Eliquis, newly launched oncology/rare disease drugs) continues to deliver mid-single-digit operational growth (above +5% YoY) and its late-stage pipeline yields 2-3 significant approvals (>$500M potential) over the next 18-24 months, then it could stabilize revenue around its $60B guidance range and see a modest re-rating to a 12-13x forward...

Full PFE Analysis

UTHR5.0/10

If United Therapeutics successfully executes the commercial launch and market penetration of Ralinepag and continues to expand the Tyvaso franchise through new formulations and indications, then the company could achieve a sustainable mid-to-high single-digit revenue growth rate annually, leading to EPS growth that justifies a premium valuation multiple. This is bullish because the market may be u...

Full UTHR Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and Comirnaty contracts offer stability, but these are incremental gains for a company of Pfizer's scale....

Full PFE Analysis

UTHR5.0/10

United Therapeutics continues to present a compelling long-term narrative driven by its robust pipeline, particularly with the positive Phase 3 results for Ralinepag and Tyvaso nebulized treprostinil, expanding its addressable markets in pulmonary hypertension and idiopathic pulmonary fibrosis. The company maintains a strong balance sheet with healthy cash flow generation. However, achieving a 10x market capitalization ($236.4 billion) within 3-5 years remains highly improbable for an establishe...

Full UTHR Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.